Clinical trials: glp1 Agonist
Obesity in Children, Bone Strength
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 receptor agonists (GLP-1RAs) as compared to those…
- Conditions
- Obesity in Children, Bone Strength, GLP - 1, Lifestyle Modification
- Trial name
- NCT06903923
- Testing
- GLP-1 receptor agonist, Lifestyle intervention
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Virginia
Spinal Cord Injuries, Type 2 Diabetes
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition.
- Trial name
- NCT06706284
- Testing
- Semaglutide Injectable Product
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Marzieh Salehi
Obesity
Continuous Wearable Biometric Monitoring in Adults Undergoing Obesity Treatment (SMART-BMI)
The goal of this clinical trial is to learn if a smart ring that tracks health signals can help adults lose weight and improve their health during obesity treatment.
- Trial name
- SMART-BMI (NCT07736729)
- Testing
- Biometric-informed care, Control Arm: Standard Care
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Jeff Reeves
Diabetes Mellitus, Type 2
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: 60 patients…
- Trial name
- NCT03878706
- Where
- Greece
- Volunteers
- 240 people
- Sponsor
- University of Athens
Diabetes Mellitus, Type 2
TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy
To assess the TANTALUS therapy in type 2 diabetic patients who can not tolerate GLP-1 agonist due to unacceptable side effects; and to assess the TANTALUS therapy in type 2 diabetic patients who do not sufficiently benefit from…
- Trial name
- NCT01303315
- Testing
- TANTALUS System
- Where
- 13 sites in Czechia, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- MetaCure (USA), Inc.
Obesity, Overweight
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable…
- Trial name
- NCT06584916
- Testing
- Orforglipron
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Eli Lilly and Company
Atrial Fibrillation, Overweight and Obesity
Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients
The purpose of this pilot study is to assess the feasibility of a double-blind, randomized placebo-controlled trial of semaglutide 2.4 mg subcutaneously once weekly on top of standard care compared to standard care alone.
- Trial name
- SOCRATES-AF (NCT04885634)
- Testing
- Semaglutide Injectable Product
- Sponsor
- Axel Brandes
Sarcopenia
Creatine Supplementation During GLP-1a Therapy
GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of…
- Trial name
- NCT07625202
- Testing
- Dietary supplementation during a 12 week resistance-training program (creatine)
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Type 1 Diabetes Mellitus
SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by progressive destruction of pancreatic beta cells mediated by autoreactive T lymphocytes, resulting in absolute insulin deficiency.
- Trial name
- SHIELD-T1D (NCT07614412)
- Testing
- Recombinant Zoster Vaccine (Shingrix; RZV), Semaglutide (Ozempic®)
- Where
- Saudi Arabia
- Volunteers
- 240 people
- Sponsor
- Ministry of Health, Saudi Arabia
Type 2 Diabetes Mellitus
The Effects of Bethanechol on Glucose Homeostasis
Xenin-25 and glucose-dependent insulinotropic polypeptide (GIP) are hormones produced in the intestine that are released into the blood immediately after ingestion of a meal.
- Trial name
- NCT01434901
- Testing
- Bethanechol (25 mg), Bethanechol (50 mg), Bethanechol (100 mg)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Type 2 Diabetes
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.
The purpose of this study is to evaluate the impact of different ligands of GPR 119 (a G protein-coupled receptor in the intestine) on the secretion of the incretin hormones, GLP-1 and GIP.
- Trial name
- NCT01043445
- Testing
- GPR 119 agonist, 2-oleyl glycerol, Oleic acid, Vehicle
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Glostrup University Hospital, Copenhagen
Type 2 Diabetes, Systolic Hypertension
Blood Pressure Outcomes With Liraglutide Therapy
Purpose: The purpose of this study is to further study the mechanism by which liraglutide, a relatively new anti-hyperglycemic medication, might lower blood pressure in patients with Type 2 diabetes and high blood pressure.
- Trial name
- BOLT (NCT01755572)
- Testing
- Liraglutide
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Mount Sinai Hospital, Canada
Morbid Obesity, Metabolic Syndrome
Impact GLP-1 Agonists Following Bariatric
Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic…
- Conditions
- Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus, Hypertension
- Trial name
- NCT06132477
- Testing
- GLP-1 receptor agonist
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Missouri-Columbia
Rectal Cancer Patients, Obesity &Amp; Overweight
Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer
The goal of this clinical trial is to see if adding a weight loss medication (GLP-1 receptor drug) to patients with an increased BMI receiving treatment for rectal cancer prior to surgery (total neoadjuvant chemoradiotherapy)…
- Conditions
- Rectal Cancer Patients, Obesity &Amp; Overweight, Locally Advanced Rectal Cancer (LARC), Total Neoadjuvant Therapy
- Trial name
- NCT07314528
- Testing
- GLP-1 receptor agonist, Total neoadjuvant therapy (TNT)
- Volunteers
- 42 people
- Sponsor
- St. James's Hospital, Ireland
Alcohol Use Disorder
The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers
A double-blind, randomized, placebo-controlled, crossover design trial was used to test the effect of exenatide on alcohol self-administration and craving following a priming dose of alcohol.
- Trial name
- NCT03645408
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Stroke, Stroke, Acute
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
Endovascular thrombectomy (EVT) is a highly effective therapy for acute ischemic stroke with large vessel occlusion (LVO). EVT was proven efficacious in selected patients with symptoms onset or last-known-well time of up to 24…
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic, Brain Diseases
- Trial name
- GALLOP (NCT05920889)
- Testing
- Semaglutide
- Where
- 2 sites in China, Hong Kong
- Volunteers
- 140 people
- Sponsor
- Chinese University of Hong Kong
Gastroparesis, Functional Dyspepsia
Effects of Liraglutide on Body Surface Gastric Mapping
Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of…
- Conditions
- Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
- Trial name
- NCT06500130
- Testing
- Body Surface Gastric Mapping
- Where
- New Zealand
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alimetry
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Type 2 Diabetes Mellitus (T2DM), Obesity (Disorder)
Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy
The goal of this clinical trial is to learn whether adding the NutriSteppe digital dietary intervention to routine medical care improves metabolic health in adults aged 21 to 65 years with type 2 diabetes mellitus, obesity, or…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Obesity (Disorder), Overweight, Metabolic Syndrome
- Trial name
- NutriSteppe (NCT07728669)
- Testing
- NutriSteppe Digital Dietary Intervention
- Where
- Kazakhstan
- Volunteers
- 120 people
- Sponsor
- Kazakh Academy of Nutrition
Spinal Cord Injuries, Insulin Resistance
Once Weekly GLP-1 in Persons With Spinal Cord Injury
Chronic spinal cord injury (SCI) results in adverse soft tissue body composition changes and an extremely sedentary lifestyle. These abrupt changes often lead to a high prevalence of cardiometabolic diseases, such as impaired…
- Conditions
- Spinal Cord Injuries, Insulin Resistance, Pre Diabetes, Obesity
- Trial name
- NCT03292315
- Testing
- Semaglutide 1MG Injection [Ozempic], No Intervention
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- James J. Peters Veterans Affairs Medical Center